-
Broad Capital Markets Experience
Andy's expertise includes IPOs and follow-on and secondary equity offerings; investment-grade, high-yield, and convertible debt offerings; and PIPE transactions.
-
Represents Companies Through All Development Stages
Andy represents emerging companies at all stages of development, advises entrepreneurs on day-to-day legal matters, and represents clients in strategic transactions and liquidity events.
-
Thought Leadership
Andy often speaks on matters related to capital markets transactions, SEC disclosure requirements, and corporate governance matters.
Andrew Hoffman is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. His practice focuses on corporate and securities work for both public and private companies across all stages of growth, as well as for financial institutions, venture capital firms, and other investors. Andy has represented clients across a wide range of industries, including software, semiconductors, life sciences, energy, financial services, manufacturing, retail, and telecommunications. He advises emerging companies at all stages of maturity, including formation, initial funding, expansion, strategic investments, and exit. Andy works with public and private companies on a range of transactions, including financings, initial public offerings, and mergers and acquisitions. He also counsels clients on matters such as general corporate law, fiduciary duties, and governance and public company disclosure, as well as reporting with the U.S. Securities and Exchange Commission.
Andy's broad capital markets experience includes initial public, follow-on, and secondary equity offerings; investment-grade, high-yield, and convertible debt offerings; and private investment in public equity (PIPE) transactions. He advises a number of public companies with respect to corporate governance, exchange-listing standards, SEC compliance and disclosure requirements, and other complex corporate and securities law matters, and frequently represents investment banks in their underwriting transactions. In addition, Andy is a regular speaker on matters related to capital markets transactions, SEC disclosure requirements, and corporate governance matters.
Andrew Hoffman is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. His practice focuses on corporate and securities work for both public and private companies across all stages of growth, as well as for financial institutions, venture capital firms, and other investors. Andy has represented clients across a wide range of industries, including software, semiconductors, life sciences, energy, financial services, manufacturing, retail, and telecommunications. He advises emerging companies at all stages of maturity, including formation, initial funding, expansion, strategic investments, and exit. Andy works with public and private companies on a range of transactions, including financings, initial public offerings, and mergers and acquisitions. He also counsels clients on matters such as general corporate law, fiduciary duties, and governance and public company disclosure, as well as reporting with the U.S. Securities and Exchange Commission.
Andy's broad capital markets experience includes initial public, follow-on, and secondary equity offerings; investment-grade, high-yield, and convertible debt offerings; and private investment in public equity (PIPE) transactions. He advises a number of public companies with respect to corporate governance, exchange-listing standards, SEC compliance and disclosure requirements, and other complex corporate and securities law matters, and frequently represents investment banks in their underwriting transactions. In addition, Andy is a regular speaker on matters related to capital markets transactions, SEC disclosure requirements, and corporate governance matters.
- J.D., University of Michigan Law School, 2003
- B.A., Government and English, Georgetown University, 2000Cum Laude
- Member, Business Law Section of the State Bar of California
- Affiliate Attorney, University of Michigan Law School's Entrepreneurship Clinic (2012-2013)
- Named to the 2013-2018 "Rising Stars" lists published by Northern California Super Lawyers
- State Bar of California
- J.D., University of Michigan Law School, 2003
- B.A., Government and English, Georgetown University, 2000Cum Laude
- Member, Business Law Section of the State Bar of California
- Affiliate Attorney, University of Michigan Law School's Entrepreneurship Clinic (2012-2013)
- Named to the 2013-2018 "Rising Stars" lists published by Northern California Super Lawyers
- State Bar of California
Select Representations
- Representation of issuers in numerous public offerings, including Amphastar Pharmaceuticals, Apigee, Arista Networks, Barracuda Networks, ESS Tech, Ekso Bionics, Elastic, Livongo, Nutanix, Pacific Biosciences of California, Pulse Biosciences, ProSomnus, Spark I, SVB Financial Group, and Talend
- Representation of underwriters such as BofA Securities, Goldman Sachs, Jefferies, J.P. Morgan, KeyBank, Morgan Stanley, and Piper Jaffray in numerous public offerings
- Corporate, securities, and governance representation of numerous public companies, including Amphastar Pharmaceuticals, Arista Networks, AXT, Elastic, Pacific Biosciences of California, Pulse Biosciences, ProSomnus, Quantumscape, and Talend
- Corporate, securities, and governance representation of a wide variety of private companies ranging from seed-stage start-ups to late-stage enterprises
- Representation of venture capital and private equity investors, including Balderton, Boxer Capital, Catchlight Capital, Francisco Partners, Institutional Venture Partners, Tau Capital, and Wittington Ventures
- Acquisitions, dispositions, and other strategic transactions by numerous public and private companies, including Amphastar Pharmaceuticals, Barracuda Networks, Boardvantage, Exact Science, Pacific Biosciences of California, ProSomnus, Salesforce, and Talend
Select Representations
- Representation of issuers in numerous public offerings, including Amphastar Pharmaceuticals, Apigee, Arista Networks, Barracuda Networks, ESS Tech, Ekso Bionics, Elastic, Livongo, Nutanix, Pacific Biosciences of California, Pulse Biosciences, ProSomnus, Spark I, SVB Financial Group, and Talend
- Representation of underwriters such as BofA Securities, Goldman Sachs, Jefferies, J.P. Morgan, KeyBank, Morgan Stanley, and Piper Jaffray in numerous public offerings
- Corporate, securities, and governance representation of numerous public companies, including Amphastar Pharmaceuticals, Arista Networks, AXT, Elastic, Pacific Biosciences of California, Pulse Biosciences, ProSomnus, Quantumscape, and Talend
- Corporate, securities, and governance representation of a wide variety of private companies ranging from seed-stage start-ups to late-stage enterprises
- Representation of venture capital and private equity investors, including Balderton, Boxer Capital, Catchlight Capital, Francisco Partners, Institutional Venture Partners, Tau Capital, and Wittington Ventures
- Acquisitions, dispositions, and other strategic transactions by numerous public and private companies, including Amphastar Pharmaceuticals, Barracuda Networks, Boardvantage, Exact Science, Pacific Biosciences of California, ProSomnus, Salesforce, and Talend
- Biotech
- Capital Markets
- Clean Energy
- Climate and Clean Technologies
- Communications and Networking
- Consumer Products and Services
- Corporate
- Corporate Governance
- Corporate Life Sciences
- Data Storage and Cloud
- Emerging Companies and Venture Capital
- Fintech
- Global Generics
- Internet
- Life Sciences
- Medical Devices
- Mergers & Acquisitions
- Mobile Devices
- Mobility
- Public Company Representation
- Semiconductors
- Software
- Special Purpose Acquisition Companies (SPACs)
The Series C financing will accelerate the commercial expansion of Culture’s next-generation hardware product, the Stratyx 250, as well as fuel continued development of the company’s AI-powered Console software ecosystem. The Stratyx 250 system is engineered to provide scalable, automated, and digitally connected bioprocess capacity designed for modern biologics, cell therapy, and advanced bioprocess development needs. In parallel, Culture will expand the AI-enabled capabilities of its Console software platform, including advanced data integration, predictive modeling, and automated analysis tools intended to streamline development cycles and enhance process decision-making for customers.
The Wilson Sonsini team that advised Culture on the financing included Andrew Hoffman, Terence Desouza, Utsav Lall, Kate Kirkpatrick, Michael Murrietta, and Casey Hepburn.
- Privacy Policy
- Terms of Use
- Accessibility